First attempts were performed for advanced renal cell carcinoma and metastatic melanoma: recombinant human interleukin-2 (rhIL-2) used in these settings, was capable of favoring human T cell growth [1,2]. Here, IL2 is linked to hereditary clear cell renal cell carcinoma.